<DOC>
	<DOC>NCT01066715</DOC>
	<brief_summary>The study hypothesis is that XOMA 052 improves glycemic control in subjects with Type 2 Diabetes. Study X052078 is designed to establish efficacious dose(s) for future studies based on improvement in HbA1c.</brief_summary>
	<brief_title>Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Diagnosed with T2D (disease duration ≥ 6 months) HbA1c ≥ 6.8% and ≤ 10.0% Have been on a stable regimen of metformin monotherapy for at least 12 weeks prior to Day 0 Willingness to maintain stable diet and exercise regime throughout the study Willingness to maintain current doses/regimens of vitamins and dietary supplements through the end of the study Uncontrolled hypertension History of malignancy within 5 years History of allergic or anaphylactic reactions to humanized or murine monoclonal antibodies Advanced stage heart failure (New York Heart Association [NYHA] class 3 or 4) Clinically significant uncontrolled arrhythmias History of tuberculosis Active leg, foot, or decubitus ulcer Any significant inflammatory, rheumatologic, or systemic autoimmune disease History of chronic infections History or any symptoms of a demyelinating disease Major surgery within 3 months Female subjects who are pregnant, planning to become pregnant Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Type 2</keyword>
	<keyword>Mellitus</keyword>
</DOC>